Wuhan YZY Biopharma (HKG:2496) appointed Hu Liaoyuan as the company's chief scientific officer, according to a Friday filing with the Hong Kong Exchange.
Hu will lead the company's development strategies, along with the discovery, development and commercialization of antibodies.